Literature DB >> 14533132

Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.

Suzanne L Verheyden1, John A Henry, H Valerie Curran.   

Abstract

This study examined the reported psychological effects of different patterns of MDMA use in men and women, and how they are modified by use of other psychoactive substances. A semi-structured interview was conducted with 466 regular MDMA users, exploring the perceived acute, sub-acute and long-term subjective effects of this drug. Factor analysis established three main categories of acute effects of MDMA: (i) positive and (ii) negative effects on mental health, and (iii) physical effects. In terms of subacute effects, 83% of participants reported experiencing low mood and 80% reported impaired concentration between ecstasy-taking sessions. Factors affecting these effects included age, gender, extent of MDMA use and concomitant use of cocaine or amphetamine. The long-term effects most frequently reported included the development of tolerance to MDMA (59%), impaired ability to concentrate (38%), depression (37%) and 'feeling more open towards people' (31%). In terms of what might persuade users to stop using MDMA, their most prominent concern was the drug's long-term effects on mental health. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14533132     DOI: 10.1002/hup.529

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  38 in total

1.  A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.

Authors:  Daniel Wagner; Philip Koester; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Martin Hellmich; Joerg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2014-08-27       Impact factor: 4.530

2.  MDMA (Ecstasy) use and psychiatric problems.

Authors:  Casey R Guillot; Mitchell E Berman
Journal:  Psychopharmacology (Berl)       Date:  2006-10-24       Impact factor: 4.530

3.  Do adolescent ecstasy users have different attitudes towards drugs when compared to marijuana users?

Authors:  Silvia S Martins; Carla L Storr; Pierre K Alexandre; Howard D Chilcoat
Journal:  Drug Alcohol Depend       Date:  2007-12-18       Impact factor: 4.492

4.  Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes.

Authors:  Sylvia K Shenouda; Kurt J Varner; Felix Carvalho; Pamela A Lucchesi
Journal:  Cardiovasc Toxicol       Date:  2009-03-31       Impact factor: 3.231

5.  Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.

Authors:  Mark A Wetherell; Catharine Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2013-11-05       Impact factor: 4.530

6.  Initial deficit and recovery of function after MDMA preexposure in rats.

Authors:  K A Brennan; S Schenk
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

Review 7.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

8.  MDMA effects consistent across laboratories.

Authors:  Matthew G Kirkpatrick; Matthew J Baggott; John E Mendelson; Gantt P Galloway; Matthias E Liechti; Cédric M Hysek; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-03-15       Impact factor: 4.530

9.  The acute effects of MDMA and ethanol administration on electrophysiological correlates of performance monitoring in healthy volunteers.

Authors:  D B Spronk; G J H Dumont; R J Verkes; E R A De Bruijn
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

Review 10.  A structured review of reasons for ecstasy use and related behaviours: pointers for future research.

Authors:  Gjalt-Jorn Ygram Peters; Gerjo Kok
Journal:  BMC Public Health       Date:  2009-07-13       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.